News

Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biologicals, has entered into a co development and supply agreement with Orion Corporation for intravenous(IV) nivolumab biosimilar referencing one of the world`s most widely used cancer immunotherapies � bringing two companies together to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients across cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients � and to help health systems stretch every euro of their oncology budgets further. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe � underscoring the scale of the opportunity that high-quality biosimilars can unlock for patients and healthcare systems across the region. Under the agreement, Orion will hold the exclusive right to register, market, distribute and sell the nivolumab biosimilar across Europe, and will act as the Marketing Authorisation holder in the territory. Shilpa Biologicals will lead product development and serve as the exclusive long-term commercial manufacturer and supplier for the European market from its advanced biologics facility in Dharwad, India. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments, in addition to supply revenue over the life of the partnership.

Shilpa Biologicals, a material subsidiary of Shilpa Medicare, announced the commissioning of a state-of-the-art Antibody�Drug Conjugate (ADC) GMP manufacturing facility, purpose-built and designed to meet global regulatory approval standards including US FDA, EMA, and other major health authority requirements. The facility is fully operational, with GMP qualification protocols now actively underway, placing Shilpa on a clear path to commercial readiness. This commissioning reinforces Shilpa`s commitment to high-value biologics, complex oncology Drug Substance platforms, and innovation-driven GMP manufacturing. It is a decisive step in its long-term strategy to become a globally relevant CDMO partner for advanced oncology ADC Drug Substance manufacturing � contributing to differentiated, high-impact treatments for patients worldwide.

Shilpa Medicare announced that its wholly owned subsidiary, Shilpa Biocare intends to make a strategic equity partnership of 30.4% in Gate2Brain. The investment of Euro 7 million includes cash infusion of Euro 0.5 million, equity for services Euro 5.5 million and Euro 1 million for development of project. Gate2Brain is a Barcelona-based biotechnology company developing peptide-based delivery systems that transport therapeutics across the blood-brain barrier for the treatment of central nervous system diseases. The Company is in pre-clinical stage of product development currently.Being a strategic shareholder would allow Shilpa to participate in long-term value creation while contributing the manufacturing and regulatory depth required to bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories.

Shilpa Medicare announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 0.6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.

Net profit of Shilpa Medicare rose 642.87% to Rs 107.79 crore in the quarter ended March 2026 as against Rs 14.51 crore during the previous quarter ended March 2025. Sales rose 32.09% to Rs 436.99 crore in the quarter ended March 2026 as against Rs 330.82 crore during the previous quarter ended March 2025.For the full year,net profit rose 210.81% to Rs 243.33 crore in the year ended March 2026 as against Rs 78.29 crore during the previous year ended March 2025. Sales rose 19.62% to Rs 1538.87 crore in the year ended March 2026 as against Rs 1286.43 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales436.99330.82 32 1538.871286.43 20 OPM %27.3923.94 -28.2524.73 - PBDT126.0474.65 69 402.87265.90 52 PBT95.4245.86 108 283.15152.91 85 NP107.7914.51 643 243.3378.29 211 Powered by Capital Market - Live News